Fourth Patient Commences StemSmart MSC Treatment
Filed with ASX · · 4 pages · English
• Four patients in Cohort 1 with fistulising Crohn’s disease are now undergoing treatment with NSB’s patented StemSmart™ MSC product. • Real-world treatment data from this Special Access Program will directly inform design of NSB’s planned Phase 2 clinical trial. • First round of patient treatment results expected in January 2026. • Special Access Scheme Category B provides treatment for patients
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- 2025 Annual Report & Appendix 4E
- Previous StemSmart Studies Support Renal Transplantation
- Experienced Cell Therapy Executive Appointed CEO
- StemSmart Acquisition Complete
- Previous StemSmart Studies Demonstrate Clinical Response
Later from Neuroscientific Biopharmaceuticals
- Trading Halt
- Successful Clinical Results Achieved under Special Access
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Remarkable Results from Patients treated with StemSmart
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals